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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) has a great impact on
patient’s health-related quality of life (HRQoL). The aims of this study were: 1) to
assess the generic and disease specific HRQoL of COPD patients, and 2) to evaluate
the influence of age and lung function on the patient’s HRQoL. METHODS: In this
observational, cross-sectional study the following information was obtained: age,
lung function (post-bronchodilator forced expiratory volume in one second [FEV1])
and HRQoL (generic: EuroQol five-dimension questionnaire [EQ-5D], disease spe-
cific: St. George’s Respiratory Questionnaire [SGRQ]). Multiple linear regression
model was applied to analyze the effect of age and FEV1 on the HRQoL. RESULTS:
Data collected from 170 patients (mean age 63.8 years, 41.8% male) were analyzed.
The mean EQ-5D score was 0,55 (SD0,21) and the mean SGRQ total score was
56,22% (SD16,19). The multiple linear regression model was successfully applied
to describe the effect of age and FEV1 on the patient’s HRQoL measured by either
EQ-5D (R20,47) or SGRQ (R20,64). Both generic and disease-specific HRQoL were
related with age and lung function (p0.005). CONCLUSIONS: SGRQ and EQ-5D
appear to be reliable and valid for the assessment of HRQoL in COPD patients and
may be used as a non-invasive patient-centered monitoring system as a guide for
the management of COPD. Due to the simplicity of EQ-5D, the use of this instru-
ment can be recommended within routine clinical practice.
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OBJECTIVES:We aimed to explore patients’ perceived positive and negative factors
associated with the use of pharmacological-behavioral combination therapy to
smoking cessation. METHODS: Each patient who visited a drug dependent treat-
ment center was assessed using structured clinical interviews and the Fagerström
Test for Nicotine Dependence (FTND). In-depth interviews were conducted with
patients who agreed to participate in the study. These patients were treated with
behavioral therapy combined with bupropion or nicotine gum and followed up for
three consecutive months. The interview responses were recorded, transcribed
and organized thematically based on emerging codes using an inductive analysis.
RESULTS: Seventeen key informants participated in this study and the mean age
was 38.2 years. Their FTND score varied from 3.0-5.0 and the number of cigarettes
smoked was 3-40 per day. Among these patients 11.8% were able to quit smoking
within 1 month, 29.4% within 2 months, 29.4% within 3 months, and 29.4% could
not quit smoking in any period of the study. Supportive factors to smoking cessa-
tion included supports from family and colleagues, poorer health, role model for
acquaintances, household cost saving, practical advice from encouraging physi-
cians, fear of social blame, smoking-free policy at workplace, and the patients’
proactive strategies to avoid smoking temptation. Nevertheless, some barriers to
smoking cessation were lacking in initiative and readiness to quit smoking; lacking
of family support; incompliance to pharmacological-behavioral therapy; gaining
weight; triggers such as nicotine withdrawal symptoms, stress, being in a party
with smokers; using tobacco as a substitute of other substance; and inconvenient
service time and facility at the treatment center. CONCLUSIONS: This study pro-
vides a framework of interrelated social factors associated with the use of pharma-
cological-behavioral combination therapy to smoking cessation. There is a need for
developing tobacco dependence treatment programs and enabling factors tailored
to meet the needs of patients.
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OBJECTIVES:Most studies assumed defaulters to be similar to smokers in smoking
cessation programmes. Thus, the objective of this qualitative study was to explore
perceptions held by QSC defaulters towards QSC service provision. This study also
examined the smoking and smoking cessation beliefs among the defaulters.
METHODS: Drawing from the patients’ register at two different QSC settings; one
being managed by a team of physicians, medical assistants and nurses while an-
other is managed by the pharmacists, 14 current adult smokers were interviewed
face-to-face, from May 2010 to March 2011. Interviews were audio-recorded and
transcribed verbatim. The data were analyzed using thematic analysis to generate
codes, categories and subsequently themes. RESULTS: This heterogeneous sub-
group of smokers revealed shared ambivalence towards smoking and smoking
cessation, indicating the underlying unreadiness to quit smoking and low self-
efficacy. The dynamic interaction between components of the QSC such as the
degree of relationship established between the health care providers and the effi-
cacy and availability of smoking cessation aids (SCA) were being perceived as ex-
trinsic motivational cues to enable these smokers to quit smoking. Overall these
smokers described the barriers encountered mirrored the unmet expectation; com-
prising of the lack of expected skills and poor attitudes in the health care providers
and the perceived unavailability and ineffective formal smoking cessation aids
provided at the QSC. CONCLUSIONS: It is necessary to optimize the interplay of
extrinsic motivational cues (health care provider and SCA’s factors) in order to
steer these smokers to quit smoking using the QSC approach. This study serves to
underline the need to address a tailored stepped-care approach in these smokers in
relation to gender, socio-economic status and nicotine dependence level, encom-
passing a wider stance in the tobacco control policy.
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THE EFFECT OF OMALIZUMAB ON UNSCHEDULED HEALTHCARE RESOURCE
UTILISATION AND HEALTH-RELATED QUALITY OF LIFE IN UK CLINICAL
PRACTICE: THE APEX STUDY
Barnes N1, Radwan A2, Percival F3
1Barts and The London NHS Trust, London, UK, 2Novartis Pharmaceuticals UK Limited, Surrey,
UK, 3pH Associates, Marlow, UK
OBJECTIVES: The efficacy and safety of omalizumab for the treatment of severe
persistent allergic asthma have been demonstrated in randomised controlled clin-
ical trials. However, there are limited ‘real world’ data on its effects on healthcare
resource utilisation or health-related quality of life (QoL) in UK clinical practice.
METHODS: A 10 centre retrospective observational study (APEX) compared 12
months pre- versus 12 months post-omalizumab initiation in patients aged 12
years with severe persistent allergic asthma. All patients received 1 dose of
omalizumab. Hospital records were reviewed to obtain data on hospital resource
use and routinely used QoL measures e.g. Asthma Quality of Life Questionnaire
(AQLQ ) at baseline (pre-omalizumab), 16 weeks and up to 12 months following
omalizumab initiation. RESULTS: Mean Accident and Emergency department at-
tendances fell by 70% from 1.52 per patient in the 12 months pre-omalizumab to
0.46 in the 12 months post-omalizumab (p0.001). Similarly, mean in-patient hos-
pital admissions fell by 61% from 1.30 to 0.51 (p0.001) and mean in-patient bed
days fell by 70% from 9.10 to 2.74 (p0.001) per patient. In the subgroup of patients
hospitalised for asthma in the 12-months pre-omalizumab (n81), mean in-pa-
tient hospital admissions fell by 70% from 2.19 to 0.65 (p0.001) and mean in-
patient bed days fell by 74% from 14.86 to 3.83 (p0.001) per patient. Other resource
use, such as outpatient attendances (excluding visits made solely for omalizumab
administration), nurse appointments and telephone consultations remained un-
changed following omalizumab initiation. QoL data were not available for all pa-
tients at every time point. However, where data were available, mean AQLQ scores
increased from 3.09 at baseline to 5.01 at 16 weeks (n90) and to 5.22 at 12 months
(n29). CONCLUSIONS: Treatment with omalizumab is associated with a signifi-
cant reduction in unplanned hospital resource utilisation and significant improve-
ments in patients’ QoL.
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OBJECTIVES:Drug use review for the treatment of asthma and assess the impact of
the administrative program to optimize the use of drugs in the Samara region in
2008-2010. METHODS: In 2008 retrospective analysis of drug use in ambulatory
practice based on a database of 90,196 paid prescriptions patients with bronchial
asthma in the Samara region. An analysis of 155 history of 15 clinics. Data on the
consumption of drugs were presented with the ATC/DDD methodology in the form
of DDD/1000 inhabitants day. After the analysis has developed a program that
includes training, administrative controls over the discharge of drugs, medica-
tions, and form a formal application form. In 2009, the evaluation of the implemen-
tation of the optimization program by re-examining the consumption of drugs (105
318 prescriptions paid for) and analysis of hospital records (143 history) RESULTS:
Use of basic products in 2008 amounted to 380, including inhaled corticosteroids
(ICS) was 286, medications to relieve symptoms - 485 DDD 1000 inhabitants/day. In
2009, use of basic drugs increased by 1.6 times to 621, the consumption of inhaled
corticosteroids has increased by 1.7 times to 502 DDD per 1000 inhabitants/day, (p
0.001). In 2009 compared to 2008 the number of patients with nocturnal symp-
toms dropped from 52% to 37%; of hospitalization from 47% to 25%; ambulance call
from 40% to 23%, respectively (p 0.001). CONCLUSIONS: The introduction of a
rational program for the use of drugs with the use of administrative controls in 2009
allowed the drug to optimize the consumption of patients with asthma to improve
asthma control in clinical practice and to reduce the costs of the use of medical
resources.
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OBJECTIVES: This study analyses consumption patterns of fluoroquinolones and
documents in vitro resistance of S. pneumoniae to fluoroquinolones in ambulatory
care in Belgium. METHODS: Data on fluoroquinolone consumption were derived
from IMS Health. Volume of consumption was expressed in terms of the number of
defined daily doses per 1,000 inhabitants per day (DID). Consumption was valued at
public prices pertaining to the year or month of consumption. Respiratory blood
isolates were taken from adults to test in vitro susceptibility of S. pneumoniae to
levofloxacin and moxifloxacin. The S. pneumoniae strains were isolated in 15 clinical
laboratories throughout Belgium. A hundred blood isolates per year were at ran-
dom selected from 2004 to 2009. Susceptibility and resistance of S. pneumoniae was
expressed using the Clinical and Laboratory Standards Institute breakpoints.
RESULTS: Fluoroquinolone consumption increased from 24.1 million € in 1993 to a
maximum of 44.4 million € in 2002, and then decreased to 35.0 million € in 2009. The
volume of fluoroquinolone consumption has fallen consistently from 3.00 DIDs in
2003 to 2.66 DIDs in 2009. Fluoroquinolones were primarily used to treat urinary
tract infections (36% of consumption, volume of 0.95 DIDs) and lower respiratory
tract infections (26% of consumption, volume of 0.70 DIDs). The minimum inhibi-
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tory concentration (MIC) distribution of moxifloxacin and levofloxacin in S. pneu-
moniae isolates remained stable during 2004-2009 and resistance to moxifloxacin
and levofloxacin was low (1%). Moxifloxacin was the most potent fluoroquinolone
available for treatment of S. pneumoniae infections in Belgium with MIC90 of 0.19
mg/L. CONCLUSIONS: The volume of fluoroquinolone use remains well controlled
and fluoroquinolones were primarily used in those indications where they have
been shown to yield clinical benefit. The use of fluoroquinolones has not led, to
date, to an increase in the rate of pneumococcal resistance to fluoroquinolones.
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OBJECTIVES: Chronic rhinosinusitis (CRS) is a debilitating chronic condition with
substantial burden of illness. The purpose of this study was to obtain information
to inform a budget impact model for balloon sinuplasty (BSP) in CRS in Asia Pacific
(Australia, China, India, Japan, South Korea). METHODS: Three systematic reviews
of the literature were undertaken (October 2010 – February 2011) using Medline,
Embase and Cochrane to identify prevalence of CRS in the region, clinical evidence
for BSP and economic evidence for CRS. Manual searching, including HTA data-
bases and interviews with clinicians in each country, supplemented the review.
RESULTS: A total of 171 epidemiological, 50 clinical and 95 economic articles were
identified. After title/abstract and full text review, 14 epidemiological, 14 clinical
and 6 economic articles remained. However, population-based prevalence of CRS
was only reported for Japan (0.05%) and Korea (1% to 7%), with the remainder of the
articles discussing risk factors or subcategories of the disease. Manual searching of
key country specific journals, published articles and guidelines, the internet (in-
cluding Mandarin search) and secondary data sources identified prevalence of CRS
for Australia (9%) and India (8%), but not China. Two comparative (non-ran-
domised) studies of BSP and nine case-series (n10 patients) were identified. BSP
was reported to be favourable in terms of safety and efficacy with high ostia pa-
tency, shorter recovery time, improved symptoms and patient satisfaction. Eco-
nomic studies confirmed the high economic burden of CRS. One economic study on
BSP was identified which, from a USA payer perspective, demonstrated lower cost
than conventional endoscopic sinus surgery predominantly due to the lower cost
of revision surgery and associated shorter surgical time. CONCLUSIONS: Tradi-
tional data sources provide limited information on prevalence of CRS in Asia-
Pacific. BSP appears to have value both clinically and economically, however fur-
ther research is required to accurately quantify these benefits.
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OBJECTIVES: To identify factors that affect smoking status in Greece.METHODS:A
strictly-structured questionnaire-based telephone survey was conducted to a sam-
ple of 6559 individuals, 18 years, representative of the Greek population and
stratified according to age, sex and place of residence. Participants were requested
to answer to questions, regarding, among others, smoking status, family/marital
status, self-reported quality-of-life, presence of a health problem, level of educa-
tion, family income and type of occupancy. The survey took place from January to
March 2011. A logistic regression analysis was conducted to identify the factors
that influence smoking status (non-smokers vs. smokers, ex- vs. current smokers).
RESULTS: Distinguishing between non-smokers vs. smokers, higher income (Odds
Ratio: 1.08, 95% Confidence Interval: 1.03-1.13), absence of a health problem (OR:
1.31, 95%CI: 1.14-1.50) and living single (ORs: 1.46, 1.18 and 2.25 for singles, widows/
widowers and divorcees, respectively) were associated with a greater risk of smok-
ing. Female gender, enhanced quality-of-life status, and higher levels of education
had a protective influence on the probability of smoking (ORs: 0.69, 0.79, 0.91).
Comparing ex- and current smokers, the regression showed that the probability of
quitting was associated with higher levels of education (OR: 0.91, 95%CI: 0.88-0.95),
increasing age (OR: 0.97, 95%CI: 0.95-0.97) and enhanced quality-of-life (OR: 0.88,
95%CI: 0.80-0.98), whereas, women (OR: 1.81, 95%CI: 1.46-2.24), people without
health-related problems (OR: 1.62, 95%CI: 1.32-1.99) and those with a higher income
(OR: 1.05, 95%CI: 1.01-1.13) had increased probability of being current smokers.
Pensioners and students were more likely to have quitted smoking than other
occupational groups. All reported values are statistically significant (p0.05).
CONCLUSIONS: Socioeconomic factors significantly influence smoking status and
the decision to quit. In Greece, as in other countries with a high prevalence of
smoking, evidence like the aforementioned can serve as important inputs in the
health policy decision-making process.
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OBJECTIVES: NHS Stop Smoking Services provide various options for support and
counselling. Most services have evolved to suit local needs without any retrospec-
tive evaluation of their efficiency. Objective was to describe the structure and out-
comes associated with different services. METHODS: Local service evaluations
were done in three primary Care Trusts (PCTs) by conducting standardised inter-
views with key personnel in addition to extraction and analysis of data from 400
clients accessing the service after 1st April 2008 in each PCT. RESULTS: The PCTs
varied in geography, population size and quit rate (47%-63%). Services were deliv-
ered by PCT-led specialist teams (PCT1), community-based health care providers
(PCT3) and a combination of the two (PCT2) with varying resources and interven-
tions in each. Group support resulted in the highest quit rates (64.3% for closed
groups v 42.6% for one-to-one support (PCT1)). Quit rates were higher for PCT (75%)
versus GP (60%) and pharmacist-delivered care (40%) where all existed in the same
model (PCT2). The most-prescribed therapy was NRT (56%-65%), followed by va-
renicline (25%-34%), counselling alone (6%-8%) and bupropion (2%-4%). Quit rates
for NRT at 4 weeks were 43%-55% across the 3 PCTs; 60% -81% for varenicline and
38%-91% for bupropion. CONCLUSIONS: The results suggest that service structure,
method of support, healthcare professional involved and pharmacotherapy all play
a role in a successful quit. Services must be tailored to support individual needs
with patient choice and access to varied services being key factors.
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OBJECTIVES: GETQUIT clinics (GQCs) are free, US-based, 1-hour workshops spon-
sored by Pfizer, and designed to support smokers planning to quit. The clinics are
hosted by physicians and tobacco-treatment specialists. We evaluated the impact
of the GQCs on attendees’ knowledge around developing a quit plan, readiness to
change, and intent-to-act regarding smoking cessation. METHODS: Subjects pre-
enrolled at GQCs between March-November 2010 were invited to a pre-clinic tele-
phone interview and, within 7 days of attendance, to a post-clinic telephone inter-
view. A survey was administered at both interviews to compare changes in
responses. Incentives were offered to subjects completing both interviews. Change
in subject knowledge was assessed by comparing pre- vs. post-clinic level of agree-
ment with seven statements on developing a quit plan. Readiness-to-change was
based on the proportion of subjects progressing 1 stage on the Transtheoretical
Model Stages of Change-Short Form. Intent to act was assessed post-clinic only.
Subject demographics, smoking history and nicotine dependence were also
obtained. RESULTS: Of 3147 persons contacted, 369 completed both interviews.
Mean age was 51.4y, 69% were female. All knowledge endpoints showed significant
improvement post-clinic (p0.0001 for all). Although there was no significant im-
provement in readiness-to-change overall, there were larger improvements among
those in earlier stages of change pre-clinic (Contemplators 25% improvement vs.
Preparation 5%). Post-clinic, 38% of attendees had contacted their doctor about
quitting smoking and 44% of the remainder intended to do so within the next 2
weeks. Approximately 90% agreed or strongly agreed that they viewed their health
care provider as a partner in managing their overall health since attending the
GETQUIT clinic.CONCLUSIONS: Effecting successful behavior change requires sus-
tained effort and multiple techniques. The GQCs, although brief, significantly im-
proved attendees’ knowledge on how to quit successfully. Additionally, more than
a third of attendees reported engaging with their doctors about quitting after at-
tending.
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OBJECTIVES: To estimate the economic consequences of an ameliorated adher-
ence to GOLD guidelines recommendations for Chronic Obstructive Pulmonary
Disease (COPD) management in the Italian clinical practice. METHODS: A Markov
model compares the current approach for COPD treatment (CURRENT strategy)
with a strategy of care (GOLD GL strategy) mainly consisting of universal spirome-
try-based staging, alignment of the pharmacological therapy to guideline recom-
mendations implemented by expert opinion. Drug consumption of the CURRENT
strategy is based on data of 3113 patients collected by three Local Health Units. The
consumption of other health resources, i.e. medical visits and inpatient care, is
estimated from a multicentre observational Italian study, from which also their
variation as a consequence of the improved adherence to GOLD is derived. Costs
are calculated from the National Health Service perspective, based on published
analyses and current prices and tariffs. RESULTS: The adoption of the GOLD GL
strategy for the treatment of the over 1250,000 prevalent Italian COPD patients
results in a cost increase of 19 million Euros for the restaging and of 100 million
Euros for the redefinition of the clinical management strategy, compared to the
CURRENT strategy. Furthermore, the adaptation of the pharmacological therapy to
GOLD recommendations, (essentially a higher usage of long-acting beta agonist/
corticosteroid combinations), increases costs by more than 320 million Euros. On
the other side, the consumption of other health care resources is reduced by 44%,
an estimated cost saving of more than 850 million Euros. The net cost saving
associated with the improved GOLD guideline adoption results in 410 million Euros.
CONCLUSIONS: The model estimates that the adoption of GOLD guidelines in the
Italian clinical practice is associated to an increase of expenses for pharmaceuti-
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